University Hospitals- Seidman Cancer Center

Cleveland, Ohio 44106

5 studies enrolling now · 43 studies all time

What they study most

ALL, Childhood, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Advanced Clear Cell Renal Cell Carcinoma, Advanced Malignancies, Advanced Solid Tumors, Biliary Tract Cancer, Bladder Cancer, Brain Cancer, Brain Tumor, Breast Cancer, Cancer

Studies at this site

• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation — Recruiting now
• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study — Recruiting now
• Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring — Recruiting now
• A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer — Recruiting now
• Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma — Recruiting now
• LMY-920 for Treatment of Relapsed or Refractory Myeloma — Recruiting now
• A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM — Running, not enrolling
• Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) — Running, not enrolling
• A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer — Running, not enrolling
• Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers — Stopped early
• A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer — Running, not enrolling
• Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) — Stopped early
• CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma — Completed
• A Long-term Follow-up Study of Patients Who Received VOR33 — Stopped early
• Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant — Stopped early
• Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS — Stopped early
• PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma — Running, not enrolling
• Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects — Completed
• Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies — Completed
• A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System — Stopped early
• An Investigation of TAS-119 Monotherapy — Stopped early
• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) — Completed
• Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma — Completed
• Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma — Completed
• CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab — Completed
• ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients — Completed
• Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma — Stopped early
• ASCO Survey on COVID-19 in Oncology (ASCO) Registry — Status unconfirmed
• Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC — Status unconfirmed
• Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease — Completed
• Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas — Completed
• Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery — Completed
• Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer — Completed
• Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer — Status unconfirmed
• Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer — Completed
• Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma — Status unconfirmed
• Music Therapy in Sickle Cell Transition Study — Completed
• Music Therapy in Sickle Cell Pain Mixed Methods Study — Completed
• MUSic Therapy to Improve Quality Of Life in Sickle Cell Disease (MUSIQOLS) — Completed
• Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma — Stopped early
• BEATS 2: Music Therapy in Sickle Cell — Completed
• A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma — Completed